Inhaler Devices: What Remains to be Done?

被引:36
作者
Smith, Ian J. [1 ]
Bell, John [2 ]
Bowman, Nic [3 ]
Everard, Mark [4 ]
Stein, Stephen [5 ]
Weers, Jeffry G. [6 ]
机构
[1] Harston, Cambridge, England
[2] Woodbank, Loughboroughm, Leics, England
[3] Pfizer Cambridge Res Ctr, Cambridge, England
[4] Sheffield Childrens Hosp, Western Bank, Sheffield, S Yorkshire, England
[5] 3M Drug Delivery Syst, St Paul, MN USA
[6] Novartis Pharmaceut, San Carlos, CA USA
关键词
inhaler device; metered dose inhaler; dry powder inhaler; DRY-POWDER INHALERS; ASTHMA; THERAPY; COPD;
D O I
10.1089/jamp.2010.0853
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
The 1000 Years of Pharmaceutical Aerosols Conference convened posing the question; "what remains to be done?" When applying this question to the topic of inhaler devices, two hugely different perspectives could be taken. On the one hand, it could be argued that because there is an array of delivery systems available and the industry, prescribing physicians and patients alike have considerable choice, why would we believe it necessary to do anything further? On the other hand, as an industry, we are constantly reminded by our "customers" that the inhaler devices available are less than adequate, and in some cases woefully inadequate, that they are not "patient" friendly, not intuitive to use and importantly do nothing to encourage the patient to take the medication as intended and as prescribed. So, taking the second point of view as more reflective of reality-the Voice of the Customer-our starting point must be that there is still much to do in the field of inhaler devices. The purpose of this article is to outline some key basic requirements for inhaler design and perhaps to question some of the entrenched thinking that has pervaded inhaler product design for too many years.
引用
收藏
页码:S25 / S37
页数:13
相关论文
共 19 条
[1]  
[Anonymous], 1998, The World Health Report
[2]   Nanoparticle Formulations in Pulmonary Drug Delivery [J].
Bailey, Mark M. ;
Berkland, Cory J. .
MEDICINAL RESEARCH REVIEWS, 2009, 29 (01) :196-212
[3]  
BELL J, SPECIALTY D IN PRESS
[4]   True device compliance: the need to consider both competence and contrivance [J].
Brennan, VK ;
Osman, LM ;
Graham, H ;
Critchlow, A ;
Everard, ML .
RESPIRATORY MEDICINE, 2005, 99 (01) :97-102
[5]   An audiovisual reminder function improves adherence with inhaled corticosteroid therapy in asthma [J].
Charles, Thomas ;
Quinn, Dean ;
Weatherall, Mark ;
Aldington, Sarah ;
Beasley, Richard ;
Holt, Shaun .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2007, 119 (04) :811-816
[6]  
Christensen M.C., 2004, SEEING WHATS NEXT
[7]   Pharmacokinetic, Pharmacodynamic, Efficacy, and Safety Data From Two Randomized, Double-Blind Studies in Patients With Asthma and an In Vitro Study Comparing Two Dry-Powder Inhalers Delivering a Combination of Salmeterol 50 μg and Fluticasone Propionate 250 μg: Implications for Establishing Bioequivalence of Inhaled Products [J].
Daley-Yates, Peter T. ;
Parkins, David A. ;
Thomas, Marian J. ;
Gillett, Benjamin ;
House, Karen W. ;
Ortega, Hector G. .
CLINICAL THERAPEUTICS, 2009, 31 (02) :370-385
[8]  
DAUTREBANDE L, 1962, MICROAEROSOLS PHYSL
[9]   Hollow porous particles in metered dose inhalers [J].
Dellamary, LA ;
Tarara, TE ;
Smith, DJ ;
Woelk, CH ;
Adractas, A ;
Costello, ML ;
Gill, H ;
Weers, JG .
PHARMACEUTICAL RESEARCH, 2000, 17 (02) :168-174
[10]   Budesonide Nanoparticle Agglomerates as Dry Powder Aerosols With Rapid Dissolution [J].
El-Gendy, Nashwa ;
Gorman, Eric M. ;
Munson, Eric J. ;
Berkland, Cory .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2009, 98 (08) :2731-2746